HIV Therapy Patent Landscape 2009

Table of Contents

METHODOLOGY

INTRODUCTION

1 BRIEF OUTLINE OF THE MARKET

2 A BRIEF OUTLINE OF THE PIPELINE

3 PROTECTION STRATEGIES

• 3.1 Evolution of patent filings
• 3.2 Priority patent applications
• 3.3 Extensions
• 3.4 Analysis of industrial patents over time
• 3.5 Study of the granting of US patents
• 3.6 Study of the granting of European patents
• 3.7 Evolution of the number of applicants

4 TOPOLOGY OF PATENTS IN THE SECTOR

• 4.1 Breakdown of patents into therapeutic targets
• 4.2 Breakdown of patents by application
• 4.3 Cross-analysis of the categories "applications" and "therapeutic targets"
• 4.4 Breakdown of patents by class of compounds
• 4.5 Cross-analysis of the categories "class of compound" and "therapeutic target"
• 4.6 Cross-analysis of the categories "class of compound" and "application"
• 4.7 Breakdown of the main IPC codes of patents

5 APPLICANTS

• 5.1 Analysis for the entire period (1983-2006)
  • 5.1.1 Main applicants (1983-2006)
  • 5.1.2 Collaborations (1983-2006)
  • 5.1.3 Topics protected (1983-2006)
• 5.2 Analysis for the pioneer period (1983-1992)
  • 5.2.1 Pioneer applicants (1983-1992)
  • 5.2.2 Collaborations from 1983-1992
  • 5.2.3 Topics protected (1983-1992)
• 5.3 Analysis for the intermediary period (1993-2000)
  • 5.3.1 Main applicants (1993-2000)
  • 5.3.2 Collaborations (1993-2000)
  • 5.3.3 Topics protected (1993-2000)
• 5.4 Analysis for the most recent period (2001 - 2006)
  • 5.4.1 Major applicants (2001-2006)
  • 5.4.2 Collaborations (2001-2006)
  • 5.4.3 Protected topics (2001-2006)

6 INVENTORS IN THE FIELD

• 6.1 Inventors for the entire period (1983-2006)
  • 6.1.1 The main inventors
  • 6.1.2 The experts
  • 6.1.3 Mobility of inventors
  • 6.1.4 Research teams for the entire period (1983-2006)
  • 6.1.5 Topics
  • 6.1.6 Description of the main inventors
• 6.2 Pioneer inventors (1983-1992)
• 6.3 Main inventors from 1993 to 2000
• 6.4 Main inventors from 2001 to 2006
• 6.5 Emerging inventors

7 CONCLUSION

• 7.1 No novel therapies in sight
• 7.2 Repositioning of the major industrial players
• 7.3 Market players to redefine their strategies

Figure and Tables

• FIGURE 1: NUMBER OF PEOPLE LIVING WITH HIV (2007) 1
• FIGURE 2: HIV REPLICATION CYCLE
• TABLE 1: THERAPEUTIC TARGETS EXPLORED IN THE MANY STEPS OF THE VIRAL REPLICATION CYCLE
• FIGURE 3: HIV THERAPY MARKET EVOLUTION PROSPECTS AND THE MAIN PLAYERS
• FIGURE 4: MOLECULES UNDER DEVELOPMENT BY CLASS OF ANTIVIRAL (ALREADY MARKETED)
• FIGURE 5: MOLECULES UNDER DEVELOPMENT BY CLASS OF ANTIVIRAL (NOT YET MARKETED)
• FIGURE 6: EVOLUTION IN PATENT FILINGS
• FIGURE 7: GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS
• FIGURE 8: GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS/CLOSE-UP: EUROPE
• TABLE 2: EVOLUTION OF PRIORITY FILINGS
• FIGURE 9: GEOGRAPHIC DISTRIBUTION OF EXTENSIONS
• TABLE 3: EVOLUTION OF EXTENSIONS
• FIGURE 10: EVOLUTION OF THE BREAKDOWN OF INDUSTRIAL PATENTS
• FIGURE 11: EVOLUTION OF AVERAGE GRANT TIME FOR US PATENTS
• FIGURE 12: EVOLUTION OF THE GRANTING OF US PATENTS
• FIGURE 13: EVOLUTION OF THE AVERAGE GRANT TIME OF EP PATENTS
• FIGURE 14: EVOLUTION OF THE GRANTING OF EP PATENTS
• FIGURE 15: EVOLUTION OF THE NUMBER OF APPLICANTS
• FIGURE 16: BREAKDOWN OF THE PORTFOLIO BY THERAPEUTIC TARGET
• TABLE 4: EVOLUTION OF THE BREAKDOWN BY THERAPEUTIC TARGET
• FIGURE 17: BREAKDOWN OF THE PORTFOLIO BY APPLICATION
• TABLE 5: EVOLUTION OF THE BREAKDOWN BY APPLICATION
• FIGURE 18: CROSS-ANALYSIS OF THE CATEGORIES APPLICATIONS AND THERAPEUTIC TARGETS
• FIGURE 19: BREAKDOWN OF PATENTS BY CLASS OF COMPOUND
• TABLE 6: EVOLUTION IN THE BREAKDOWN BY CLASS OF COMPOUND
• FIGURE 20: CROSS-ANALYSIS OF THE CATEGORIES CLASS OF COMPOUND AND THERAPEUTIC TARGET
• FIGURE 21: CROSS-ANALYSIS OF THE CATEGORIES CLASS OF COMPOUND AND APPLICATION
• FIGURE 22: DISTRIBUTION OF THE 20 MAIN IPC CODES
• TABLE 7: DESCRIPTION OF THE 20 MAIN IPC CODES
• TABLE 8: EVOLUTION OF THE MAIN IPC CODES
• FIGURE 23: MAIN APPLICANTS FOR THE ENTIRE PERIOD (1983-2006)
• FIGURE 24: BREAKDOWN OF THE MAIN PATENT PORTFOLIOS
• FIGURE 25: MAJOR COLLABORATIONS BY NUMBER OF JOINT FILINGS FOR THE ENTIRE PERIOD (1983-2006)
• FIGURE 26: THERAPEUTIC TARGETS OF THE MAJOR PLAYERS FOR THE ENTIRE PERIOD (1983-2006)
• FIGURE 27: APPLICATIONS OF THE MAJOR PLAYERS FOR THE ENTIRE PERIOD (1983-2006)
• FIGURE 28: CLASSES OF COMPOUNDS OF THE MAJOR PLAYERS FOR THE ENTIRE PERIOD (1983-2006)
• FIGURE 29: MAJOR APPLICANTS FROM 1983-1992
• TABLE 9: EVOLUTION OF FILINGS BY MAJOR APPLICANTS FROM 1983-1992
• FIGURE 30: THE MAJOR COLLABORATIONS BY NUMBER OF JOINT FILINGS FROM 1983 TO 1992
• FIGURE 31: THERAPEUTIC TARGETS OF THE MAJOR PLAYERS FROM 1983-1992
• FIGURE 32: APPLICATIONS OF THE MAJOR PLAYERS FROM 1983-1992
• FIGURE 33: CLASSES OF COMPOUNDS OF THE MAJOR PLAYERS FROM 1983-1992
• FIGURE 34: MAJOR APPLICANTS FROM 1993 - 2000
• TABLE 10: EVOLUTION OF FILINGS BY APPLICANT FROM 1993-2000
• FIGURE 35: THE MAJOR COLLABORATIONS AND THE NUMBER OF JOINT FILINGS FROM 1993-2000
• FIGURE 36: THERAPEUTIC TARGETS OF THE MAJOR PLAYERS FROM 1993-2000
• FIGURE 37: APPLICATIONS OF THE MAJOR PLAYERS FROM 1993-2000
• FIGURE 38: CLASSES OF COMPOUNDS OF THE MAJOR PLAYERS FROM 1993-2000
• FIGURE 39: MAJOR APPLICANTS FROM 2001 - 2006
• TABLE 11: EVOLUTION OF FILINGS BY APPLICANT FROM 2001- 2006
• FIGURE 40: THE MAJOR COLLABORATIONS AND JOINT FILINGS (2001-2006)
• FIGURE 41: THERAPEUTIC TARGETS FROM 2001-2006
• FIGURE 42: APPLICATIONS OF THE MAJOR PLAYERS FROM 2001-2006
• FIGURE 43: CLASSES OF COMPOUNDS OF THE MAJOR PLAYERS FROM 2001-2006
• TABLE 12: THE MAIN INVENTORS FOR THE ENTIRE PERIOD (1983-2006)
• FIGURE 44: EXPERTISE FACTOR FOR THE ENTIRE PERIOD
• FIGURE 45: MOBILITY OF INVENTORS
• FIGURE 46: RESEARCH TEAMS FOR THE ENTIRE PERIOD (1983-2006)
• FIGURE 47: INDUSTRIAL/INSTITUTIONAL FILINGS OF THE MAIN INVENTORS AND/OR EXPERTS
• FIGURE 48: THERAPEUTIC TARGETS PROTECTED BY THE MAIN INVENTORS AND/OR EXPERTS
• FIGURE 49: CLASSES OF COMPOUNDS PROTECTED BY THE MAIN INVENTORS AND/OR EXPERTS
• FIGURE 50: APPLICATIONS PROTECTED BY THE MAIN INVENTORS AND/OR EXPERTS
• TABLE 13: LIST OF THE MAIN INVENTORS (1983-1992)
• FIGURE 51: LIST OF EXPERTS (1983-1992)
• FIGURE 52: THE MAJOR COLLABORATIONS AMONG INVENTORS (1983-1992)
• FIGURE 53: THERAPEUTIC TARGETS OF THE MAIN INVENTORS (1983-1992)
• FIGURE 54: APPLICATIONS OF THE MAIN INVENTORS (1983-1992)
• FIGURE 55: CLASSES OF COMPOUNDS OF THE MAIN INVENTORS (1983-1992)
• TABLE 14: LIST OF THE MAIN INVENTORS (1993-2000)
• FIGURE 56: LIST OF EXPERTS (1993-2000)
• FIGURE 57: THE MAJOR COLLABORATIONS AMONG INVENTORS (1993-2000)
• FIGURE 58: THERAPEUTIC TARGETS OF THE MAIN INVENTORS (1993-2000)
• FIGURE 59: APPLICATIONS OF THE MAIN INVENTORS (1993-2000)
• FIGURE 60: CLASSES OF COMPOUNDS OF THE MAIN INVENTORS (1993-2000)
• TABLE 15: MAIN INVENTORS (2001-2006)
• FIGURE 61: LIST OF EXPERTS (2001-2006)
• FIGURE 62: THE MAJOR COLLABORATIONS AMONG INVENTORS (2001-2006)
• FIGURE 63: THERAPEUTIC TARGETS OF THE MAIN INVENTORS (2001-2006)
• FIGURE 64: APPLICATIONS OF THE MAIN INVENTORS (2001-2006)
• FIGURE 65: CLASSES OF COMPOUNDS OF THE MAIN INVENTORS (2001-2006)
• TABLE 16: LIST OF EMERGING INVENTORS
• TABLE 17: EVOLUTION OF FILLINGS BY EMERGING TOPICS
• FIGURE 66: EMERGING TOPICS BY APPLICANTS
• FIGURE 67: APPLICANTS FOR EMERGING TPPICS
• FIGURE 68: AUTHORS FOR EMERGING TOPICS